SCHEMBL3688934

SCHEMBL3688934

CC[C@@H](C(=O)O)n1c(=O)c2ccccc2n(C(C)c2c[nH]c3cccc(C)c23)c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.42
▸ CMA1 P23946 10/20 0.39
▸ GPR84 Q9NQS5 1/20 0.36
▸ DNMT1 P26358 3/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ DNMT3B Q9UBC3 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ ITGB2 P05107 1/20 0.35
▸ ICAM1 P05362 1/20 0.35
▸ ITGAL P20701 1/20 0.35
▸ MGAM O43451 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ SI P14410 1/20 0.35
▸ MGAM2 Q2M2H8 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ APAF1 O14727 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3688507 1.00 POLB (0.42) POLBCMA1GPR84DNMT1CYP2C19
SCHEMBL3685767 1.00 POLB (0.42) POLBCMA1GPR84DNMT1CYP2C19
SCHEMBL3681840 0.93 CMA1 (0.47) POLBCMA1GPR84DNMT1CYP2C19
SCHEMBL3699285 0.93 CMA1 (0.47) POLBCMA1GPR84DNMT1CYP2C19
SCHEMBL3681842 0.93 CMA1 (0.47) POLBCMA1GPR84DNMT1CYP2C19
SCHEMBL3682510 0.91 CMA1 (0.48) POLBCMA1GPR84DNMT1ITGB2
SCHEMBL3685360 0.91 CMA1 (0.48) POLBCMA1GPR84DNMT1ITGB2
SCHEMBL3688465 0.91 CMA1 (0.48) POLBCMA1GPR84DNMT1ITGB2
SCHEMBL3684612 0.90 L3MBTL1 (0.43) CMA1KMT2AMAPTL3MBTL1TP53
SCHEMBL3684609 0.90 L3MBTL1 (0.43) CMA1KMT2AMAPTL3MBTL1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188277-A1 QUINAZOLINEDIONE CHYMASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2010-05-26 — — EP claimed
WO-2009023655-A1 QUINAZOLINEDIONE CHYMASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-02-19 — — WO claimed
US-8377949-B2 Quinazolinedione chymase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-02-19 — — US disclosed
EP-2188277-B1 QUINAZOLINEDIONE CHYMASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2012-11-21 — — EP disclosed
US-20120122863-A1 Quinazolinedione Chymase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-17 — — US disclosed
EP-2188277-A1 QUINAZOLINEDIONE CHYMASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2010-05-26 — — EP disclosed
WO-2009023655-A1 QUINAZOLINEDIONE CHYMASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-02-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122863-A1 Quinazolinedione Chymase Inhibitors CMA1, CTSC, TPSG1 POLB 4209/4885CMA1 1/4885GPR84 371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback